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information on Avastin’s effectiveness led to greater reliance on the ODAC decision 
by providers. Only one other study has examined the impact of ODAC and our results 
are consistent with their findings. The impact of region on prescribing practices may 
be due to the high concentration of academic medical centers in the North east. The 
FDA needs to fully understand the impact of their advisory bodies on influencing 
providers when considering the public’s health needs.
PCN62
EvolutioN of trEatmENt Paradigms iN mEtastatiC CastratE-
rEsistaNt ProstatE CaNCEr
Khamis ZJ, Merali T
Drug Intelligence Inc., Toronto, ON, Canada
Objectives: The treatment landscape for metastatic castrate-resistant prostate 
cancer (mCRPC) has changed following the introduction of new agents abiraterone, 
denosumab and cabazitaxel in 2011, and enzalutamide in 2013. The objective of this 
study was to quantify treatment trends for mCRPC. MethOds: Chart audit data 
from patients with mCRPC was collected quarterly from 2012 to 2014 from a physi-
cian panel of urologists, uro-oncologists and medical oncologists. Data included 
patient demographics, disease characteristics, and treatment details. Treatment 
regimens were categorized into: ADT, new oral agents, or chemotherapy. The use of 
bone-targeted agents (BTAs) was also noted. Results: The percentage of mCRPC 
patients being treated with oral treatments increased from 9% in 2012 to 15% in 
2013 to 61% in 2014 across all lines of treatment. The usage of BTA in order to 
reduce the risk of skeletal related events increased from 61% to 69% to 80% over 
the three years. In addition, patients are initiating treatment with BTA sooner after 
confirmation of bone metastases on bones can. The percentage of patients initiat-
ing treatment upon confirmation of bone metastases increased by 93% from 2012 
to 2014. cOnclusiOns: There has been a strong uptake of new oral agents for the 
treatment of mCRPC. A greater proportion of patients are receiving BTA as compared 
with 2012, and physicians are now less likely to delay initiating BTA treatment.
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ObjectivOs: analizar el comportamiento de pacientes con cáncer de mama a par-
tir de la información de gastos y costos reportada en el 2013 en una aseguradora 
colombiana del régimen contributivo. MetOdOlOgíAs: a partir de la información 
de uso de servicios reportados y consolidados en el año 2013, se desarrolló un 
análisis descriptivo de los pacientes identificados con cáncer de mama afiliados 
a Coomeva-EPS, los pacientes fueron identificados por los diagnósticos según el 
código CIE-10. Se estimó, caracterizó e identificaron los costos de atención de cada 
paciente y sus variaciones por características epidemiológicas, discriminando los 
resultados por departamento. En el análisis solo se incluyen costos reconocidos 
dentro del plan de beneficios colombiano. ResultAdOs: se identificaron 2692 
pacientes únicos con cáncer de mama que correspondería a una prevalencia de 
0,092% del total de afiliados, siendo el 98% mujeres con una edad promedio de 
55 +/-12,7 años. El costo promedio anual por paciente fue de $10.385.724 con var-
iaciones importantes por regiones, siendo la población atendida en Bolívar la de 
mayor costo ($19.408.590). Desde el punto de vista de distribución geográfica la 
mayor cantidad de pacientes se encuentran en Valle del Cauca y Antioquia, pero 
en proporciones similares según la cantidad de población afiliada. Desde el punto 
de vista de intervenciones, el 11,92% recibió tratamiento quirúrgico durante ese 
mismo año. El 49,69% del costo es hospitalario y los medicamentos ambulatorios 
corresponden al 24,32% del total. cOnclusiOnes: el costo promedio por paciente 
con cáncer de mama equivale a 18,25 veces la unidad de pago por captación para el 
año 2013 y su alta prevalencia impacta en los costos, siendo el 2,08% del costo total 
de la prestación en salud para el año y el 46,03% del total de los gastos en cáncer. 
Con este análisis se justifica el diseño de estrategias de gestión específica.
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Objectives: Reimbursement of oncology treatments by Brazilian Public Health 
System (SUS) is controlled by the Authorization for High Complexity Procedures 
(APAC) system. Each treatment line has an APAC code associated with a specific 
reimbursement value that should cover all drug expenses in one month. However, 
with innovation and more expensive drugs that have been launched, these fixed 
values may not be enough to cover drug expenses. In this context, our objec-
tive was to compare costs of recommended treatments with values reimbursed 
by the APAC system. MethOds: We reviewed NCCN (National Comprehensive 
Cancer Network) guidelines for mNSCLC and analyzed recommended chemo-
therapy regimens. Regimens costs were calculated and compared to the APAC 
value for metastatic NSCLC which reimburses only 1,100.00BRL (~343.75USD) 
per month. Drugs maximum sales price for government without taxes were 
used. For the drugs that already have generics, calculations were made in two 
different ways: mean price or the lowest price. The following parameters were 
used to calculate regimens costs by milligrams approach: age 65, weight 70kg, 
and body surface 1,70m2. Results: Ten different regimens are recommended 
for metastatic NSCLC, two target therapies, four bevacizumab and two pem-
etrexed based regimens, and other 3 older regimens. By considering mean 
costs of drugs whose patents expired, the APAC value does nt cover any regi-
men. Costs ranged from 574BRL (~179,30USD) to 14,204BRL (~4,439USD). With 
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Objectives: Incorrect use of colony stimulating factors (CSF) can add unnecessary 
cost to cancer treatments and adverse events to patients. We conducted an epide-
miological study to assess the correlation between CSF use recommendations issued 
by the Brazilian Regulatory Agency of Health (ANS) and technical recommendations 
stated by international guidelines. We also analyzed the main reasons for not rec-
ommending the use of CSF, in patients during chemotherapy. MethOds: Data on 
patients treated with CSF during 2014 was retrieved from Evidências - Kantar Health 
database of administrative claims, which comprises more than 4 million people and 
46 Private Health Insurance Companies (PHIC) in Brazil. Demographic assessment, 
types of tumor, number of patients, treatment purpose, technical recommenda-
tion, ANS recommendation, reason for not recommending and class of requested 
CSF were assessed. Results: We retrieved 440 CSF requests corresponding to 322 
patients. 188 requests were recommended both technically and by ANS. In 200 
claims, CSF use was not recommended by either guidelines or ANS; and only 30 
claims were in discordance, as CSF use was recommended by guidelines but not 
by ANS. Reasons for technical non-recommendation were: requests for primary 
prophylaxis on chemotherapy regimens with risk of febrile neutropenia below 20% 
and no complicating factors (37.5%), secondary prophylaxis in palliative care set-
ting (26%) or request based on complete blood count (CBC) collected at the nadir 
of chemotherapy. cOnclusiOns: Administrative recommendations from ANS are 
in close agreement with the scientific literature. Nevertheless, despite clear inter-
national guidelines and ANS recommendation, there is still a gap in physicians’ 
knowledge about the correct indications for CSF. Continual medical education on 
this topic should emphasize the following of protocols to ensure proper CSF use.
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intROductiOn: Inequitable access to oncology care between the USA and Brazil is 
frequently attributed to delays in regulatory approval by ANVISA. Objectives: The 
purpose of this research was to estimate the differences in regulatory approval time-
lines between the FDA (USA) and ANVISA (BRA) for oncology therapies, while dis-
tinguishing between delays in manufacturer application submissions and ANVISA 
regulatory processes, to understand how these delays may create inequitable patient 
access to care. MethOds: A basket of twenty-three oncology products approved by 
ANVISA after 2002 were surveyed to evaluate the differences in regulatory submis-
sion and approval dates between the USA and Brazil The ANVISA and FDA regulatory 
approval timelines were calculated by obtaining the difference between submission 
and approval dates of each product’s regulatory applications; comparisons between 
the FDA and ANVISA timelines were drawn by taking the difference in each of the 
regulatory bodies’ average approval time for all products Delays in the manufactur-
ers’ submission for regulatory approval in Brazil were calculated by comparing the 
FDA and ANVISA application submission dates for each product. Results: The 
analysis revealed that on average there was a difference of 8.6 months between 
ANVISA and the FDA’s regulatory approval process, with ANVISA averaging approxi-
mately 449 days and the FDA 186 days from submission of an application to regu-
latory approval On average, between Brazil and the USA, the products surveyed 
demonstrated a delay in the manufacturers’ submission for regulatory approval of 
1.1 years (393 days). cOnclusiOns: The results of this study indicate that there 
are significant differences in the regulatory approval timelines between the FDA 
and ANVISA which raise significant concerns over access to equitable treatment for 
oncology patients in these two countries. Importantly, although delays in ANVISA 
approval are significant, the manufacturer’s submission timing has also consider-
ably contributed to delayed patient access to new oncology therapies in Brazil.
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Objectives: Breast cancer is the second most common cause of cancer-related 
death. Women with metastatic disease have low survival rate due in part to the 
lack of effective treatments. In 2008, the U.S. Food and Drug Administration (FDA) 
granted an accelerated approval of Avastin to treat metastatic breast cancer 
(MBC) in combination with paclitaxel. In July 2010, the Oncologic Drug Advisory 
Committee (ODAC) voted unanimously to withdraw the approval. This decision 
was contested by many including the European Medicine Agency (EMA) and the 
National Comprehensive Cancer Network (NCCN). Despite this disagreement, the 
FDA revoked the approval by the end of 2011. This study examined the impact of 
ODAC’s decision on prescribing practices in 2011. MethOds: Truven MarketScan™ 
claims data from 2006 – 2011 was used as the data source. The sample included 
women ≥ 18 years who received specific chemotherapy agent listed in the NCCN 
treatment guidelines for MBC. A difference-in-difference model compared Avastin 
use before/after the 2010 ODAC decision using colorectal cancer to form the control 
group. Results: Providers were about 41% (p< 0.00) less likely to prescribe Avastin 
after 2010. Region impacted this associated. Prescribers in North central, South 
and West were approximately 3.3 – 10.0% (p< 0.00) more likely to prescribe Avastin 
than prescribers in the Northeast. cOnclusiOns: The magnitude of the utilization 
decrease in 2011 is higher than expected. However, we speculate that conflicting 
